Tranexamic Acid Precautions and Contraindications
Absolute Contraindications
Tranexamic acid is absolutely contraindicated in patients with active intravascular clotting, subarachnoid hemorrhage (due to risk of cerebral edema and infarction), and known hypersensitivity to the drug. 1
Additional Critical Contraindications:
- Microscopic or macroscopic hematuria - can cause dangerous clot formation in the urinary tract 2
- Active thromboembolic disease during pregnancy or otherwise 3
Timing Precautions
Critical Time Windows:
For postpartum hemorrhage: TXA must be given within 3 hours of birth - administration beyond this window is suspected to be potentially harmful rather than beneficial. Efficacy decreases by 10% for every 15-minute delay. 3
For trauma: Administer within 3 hours of injury for hemorrhagic shock patients. No evidence supports benefit beyond this timeframe. 4
Route of Administration - Critical Safety Issue
FOR INTRAVENOUS USE ONLY. Serious adverse reactions including seizures and cardiac arrhythmias have occurred when TXA was inadvertently administered intrathecally instead of intravenously. 1
Safety measures:
- Clearly label syringes with "INTRAVENOUS ROUTE"
- Confirm correct route before administration
- Avoid confusion with other injectable solutions administered simultaneously
Thromboembolic Risk Management
Avoid concomitant use with prothrombotic medications including:
- Factor IX Complex concentrates
- Anti-inhibitor Coagulant concentrates
- Hormonal contraceptives 1
The thromboembolic risk is dose-dependent, with marked increase at doses ≥4g (hazard ratio 5.33). 5 For patients without shock, the absolute risk difference for thromboembolic events ranges from -0.2% to +4%. 5
Seizure Risk
TXA may cause focal or generalized seizures, particularly at high doses (>80 mg/kg total dose). 6 The risk is highest with:
- Doses 10-fold higher than recommended
- Inadvertent neuraxial administration
- Cardiovascular surgery (where higher doses are sometimes used off-label)
Monitor for: myoclonic movements, twitching, or focal seizure evidence. Consider EEG monitoring in patients with seizure history. Discontinue immediately if seizures occur. 1
Dosing Considerations by Clinical Setting
Postpartum Hemorrhage:
- 1g IV over 10 minutes (infuse at 1 mL/min to avoid hypotension)
- Second 1g dose if bleeding continues after 30 minutes or restarts within 24 hours 3
Trauma with Hemorrhagic Shock:
- 1-2g IV (15-30 mg/kg) as early as possible, preferably prehospital
- Alternative: 1g initial dose followed by 1g infusion over 8 hours 4
Hemophilia (Tooth Extraction):
- 10 mg/kg IV immediately before extraction
- Continue 10 mg/kg 3-4 times daily for 2-8 days post-extraction
- Infuse no faster than 1 mL/min 1
Renal Impairment Dose Adjustments
Mandatory dose reductions for renal dysfunction: 1
| Serum Creatinine | Dosing Adjustment |
|---|---|
| 1.36-2.83 mg/dL | 10 mg/kg twice daily |
| 2.83-5.66 mg/dL | 10 mg/kg once daily |
| >5.66 mg/dL | 10 mg/kg every 48 hours OR 5 mg/kg every 24 hours |
Visual Disturbances
Although rare in humans, retinal degeneration has occurred in animal studies at high doses. Discontinue TXA if visual or ocular symptoms develop. 1
Hypersensitivity Reactions
Anaphylactic reactions have been reported. Discontinue immediately if serious hypersensitivity occurs, provide appropriate medical management, and do not restart treatment. 1
Special Population Considerations
Pediatric Trauma:
- Role not well-studied; standardized dosing not established
- If used: administer within 3 hours of injury 4
High-Risk Bleeding Patients:
- Use high-dose regimens (30 mg/kg bolus + 16 mg/kg/h + 2 mg/kg priming) 6
Low-Risk Bleeding Patients:
- Use low-dose regimens (10 mg/kg bolus + 1 mg/kg/h + 1 mg/kg priming) to minimize seizure risk 6